Evaluation of the clinical performance of a novel chemiluminescent immunoassay for detection of anticardiolipin and anti-beta2-glycoprotein 1 antibodies in the diagnosis of antiphospholipid syndrome

Medicine (United States)

Volumn 94, Issue 46, 2015, Pages e2059-

  Zhang, Shulan ^a   Wu, Ziyan ^a   Li, Ping ^a   Bai, Yina ^a   Zhang, Fengchun ^a   Li, Yongzhe ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; AUTOANTIGEN; BETA2 GLYCOPROTEIN 1; BIOLOGICAL MARKER; PHOSPHOLIPID ANTIBODY;

ADOLESCENT; ADULT; AGED; ANTIPHOSPHOLIPID SYNDROME; AREA UNDER THE CURVE; ARTICLE; CHEMILUMINESCENCE IMMUNOASSAY; CHEMILUMINESCENCE IMMUNOASSAY KIT; CHILD; CHINA; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; KAPPA STATISTICS; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; BLOOD; EVALUATION STUDY; IMMUNOLOGY; LUMINESCENCE; MIDDLE AGED; PROCEDURES; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, ANTICARDIOLIPIN; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; AUTOANTIGENS; BETA 2-GLYCOPROTEIN I; BIOMARKERS; CHILD; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LUMINESCENT MEASUREMENTS; MALE; MIDDLE AGED; YOUNG ADULT;

EID: 84948649689     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000002059     Document Type: Article

References (20)

1. Gómez-Puerta JA, Cervera R. Diagnosis and classification of the antiphospholipid syndrome. J Autoimmun. 2014;48-49:20-25.
2. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4:295-306.
3. Bertolaccini ML, Amengual O, Atsumi T, et al. 'Non-criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010. Lupus. 2011;20:191-205.
4. Devreese KM. Standardization of antiphospholipid antibody assays. Where do we stand? Lupus. 2012;21:718-721.
5. Ruffatti A, Olivieri S, Tonello M, et al. Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification. J Thromb Haemost. 2008;6:1693-1696.
6. Forastiero R, Papalardo E, Watkins M, et al. Evaluation of different immunoassays for the detection of antiphospholipid antibodies: report of a wet workshop during the 13th International Congress on Antiphospholipid Antibodies. Clin Chim Acta. 2014;428:99-105.
7. Mahler M, Radice A, Yang W, et al. Development and performance evaluation of novel chemiluminescence assays for detection of anti-PR3 and anti-MPO antibodies. Clin Chim Acta. 2012;413:719-726.
8. Webb T, Lakos G, Swart A, et al. Clinical evaluation of a novel chemiluminescent immunoassay for the detection of anti-citrullinated peptide antibodies. Clin Chim Acta. 2014;437:161-167.
9. Persijn L, Decavele AS, Schouwers S, et al. Evaluation of a new set of automated chemiluminescense assays for anticardiolipin and antibeta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome. Thromb Res. 2011;128:565-569.
10. Mondejar R, González-Rodrguez C, Toyos-Sáenz de Miera FJ, et al. Role of antiphospholipid score and anti-b2-glycoprotein I Domain I autoantibodies in the diagnosis of antiphospholipid syndrome. Clin Chim Acta. 2014;431:174-178.
11. Meneghel L, Ruffatti A, Gavasso S, et al. Detection of IgG anti-Domain I beta2 Glycoprotein I antibodies by chemiluminescence immunoassay in primary antiphospholipid syndrome. Clin Chim Acta. 2015;446:201-205.
12. DE Moerloose P, Reber G, Musial J, et al. Analytical and clinical performance of a new, automated assay panel for the diagnosis of antiphospholipid syndrome. J Thromb Haemost. 2010;8:1540-1546.
13. Chung Y, Kim JE, Lim HS, et al. Clinical performance of anticardiolipin and antib2 glycoprotein I antibodies using a new automated chemiluminescent assay: superior thrombotic prediction of combined results measured by two different methods. Blood Coagul Fibrinolysis. 2014;25:10-15.
14. Van Hoecke F, Persijn L, Decavele AS, et al. Performance of two new, automated chemiluminescence assay panels for anticardiolipin and anti-beta2-glycoprotein I antibodies in the laboratory diagnosis of the antiphospholipid syndrome. Int J Lab Hematol. 2012;34:630-640.
15. Meneghel L, Ruffatti A, Gavasso S, et al. The clinical performance of a chemiluminescent immunoassay in detecting anti-cardiolipin and anti-b2 glycoprotein I antibodies. A comparison with a homemade ELISA method. Clin Chem Lab Med. 2015;53:1083-1089.
16. Bentow C, Swart A, Wu J, et al. Clinical performance evaluation of a novel rapid response chemiluminescent immunoassay for the detection of autoantibodies to extractable nuclear antigens. Clin Chim Acta. 2013;424:141-147.
17. Meroni PL, Borghi MO, Raschi E, et al. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol. 2011;7:330-339.
18. Pierangeli SS, Harris EN. A quarter of a century in anticardiolipin antibody testing and attempted standardization has led us to here, which is? Semin Thromb Hemost. 2008;34:313-328.
19. Despierres L, Beziane A, Kaplanski G, et al. Contribution of antib2glycoprotein I IgA antibodies to the diagnosis of anti-phospholipid syndrome: potential interest of target domains to discriminate thrombotic and non-thrombotic patients. Rheumatology (Oxford). 2014;53:1215-1218.
20. Cervera R, Conti F, Doria A, et al. Does seronegative antiphospholipid syndrome really exist? Autoimmun Rev. 2012;11:581-584.